WP4
Preclinical in vivo validation
WP4 aims to validate the therapeutic efficacy, safety, and translational potential of the MXene-based wound healing platforms in clinically relevant preclinical models. This work package will:
- Assess the antibacterial performance of MXene-PDA-Ab complexes combined with NIR photothermal therapy in a standardized murine purulent wound model, quantifying bacterial clearance, biofilm disruption, and infection resolution.
- Evaluate the regenerative potential of MXene-PDA-HATMSC complexes by analyzing wound closure rates, angiogenesis, extracellular matrix remodeling, and re-epithelialization compared to controls.
- Ensure systemic safety and biocompatibility, including histopathological evaluation of major organs and measurement of inflammatory markers, to confirm the absence of off-target effects.
- Generate clinically relevant datasets that meet pre-regulatory requirements, forming the basis for future first-in-human trials and facilitating technology transfer to industrial and clinical partners.
WP4 will provide critical evidence of efficacy and safety, enabling the MX-WOUND technology to progress toward regulatory approval and clinical translation.